Incyte's (INCY) Minjuvi, in combination with rituximab and lenalidomide, has received approval by Australia's Therapeutic Goods Administration to treat relapsed or refractory follicular lymphoma in adults, the company's Australian distributor, Specialised Therapeutics said Thursday.
The registration sets up Minjuvi as the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen to be approved in the country for this group of patients, according to the company.
Follicular lymphoma is a cancer that impacts white blood cells called lymphocytes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments